Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.84 |
| ▸ | BCHE | P06276 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 11/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.39 |
| ▸ | CDC25B | P30305 | 5/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.39 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.39 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | TACR2 | P21452 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21749221 | 1.00 | NT5E (0.84) | NT5EBCHENPC1RAB9APTPN1 | |
| SCHEMBL11418140 | 0.93 | NT5E (0.93) | NT5EBCHENPC1RAB9APTPN1 | |
| SCHEMBL11418144 | 0.93 | NT5E (0.93) | NT5EBCHENPC1RAB9APTPN1 | |
| SCHEMBL749253 | 0.91 | NT5E (1.00) | NT5EBCHENPC1RAB9APTPN1 | |
| SCHEMBL6313490 | 0.91 | NT5E (1.00) | NT5EBCHENPC1RAB9APTPN1 | |
| SCHEMBL8184232 | 0.91 | NT5E (1.00) | NT5EBCHENPC1RAB9APTPN1 | |
| SCHEMBL6313488 | 0.91 | NT5E (1.00) | NT5EBCHENPC1RAB9APTPN1 | |
| SCHEMBL8184231 | 0.91 | NT5E (1.00) | NT5EBCHENPC1RAB9APTPN1 | |
| SCHEMBL8928824 | 0.90 | NT5E (0.98) | NT5EBCHENPC1RAB9APTPN1 | |
| SCHEMBL8928920 | 0.90 | NT5E (0.98) | NT5EBCHENPC1RAB9APTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200062793-A1 | APRAMYCIN DERIVATIVES | WAYNE STATE UNIVERSITY (US) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062793-A1 | APRAMYCIN DERIVATIVES | APRT, ABCC5, MPI | NT5E 283/4885BCHE 2306/4885NPC1 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.